Published in Clin Drug Investig on January 01, 2011
Comparison of vildagliptin twice daily vs. sitagliptin once daily using continuous glucose monitoring (CGM): crossover pilot study (J-VICTORIA study). Cardiovasc Diabetol (2012) 1.20
The Effect of DPP-4 Inhibitors on Metabolic Parameters in Patients with Type 2 Diabetes. Diabetes Metab J (2014) 0.97
Everolimus and sunitinib for advanced pancreatic neuroendocrine tumors: a matching-adjusted indirect comparison. Exp Hematol Oncol (2013) 0.86
Alogliptin benzoate for management of type 2 diabetes. Vasc Health Risk Manag (2015) 0.83
Efficacy and safety of vildagliptin, Saxagliptin or Sitagliptin as add-on therapy in Chinese patients with type 2 diabetes inadequately controlled with dual combination of traditional oral hypoglycemic agents. Diabetol Metab Syndr (2014) 0.78
Exenatide extended-release; clinical trials, patient preference, and economic considerations. Patient Prefer Adherence (2013) 0.78
A scoping review of indirect comparison methods and applications using individual patient data. BMC Med Res Methodol (2016) 0.76
Effects of vildagliptin as add-on treatment in patients with type 2 diabetes mellitus: insights from long-term clinical studies in Japan. J Diabetes Metab Disord (2016) 0.75
Economic evaluation of denosumab compared with zoledronic acid in hormone-refractory prostate cancer patients with bone metastases. J Manag Care Pharm (2011) 2.25
Cost effectiveness of guanfacine extended-release versus atomoxetine for the treatment of attention-deficit/hyperactivity disorder: application of a matching-adjusted indirect comparison. Appl Health Econ Health Policy (2012) 2.06
Budget impact analysis of everolimus for the treatment of hormone receptor positive, human epidermal growth factor receptor-2 negative (HER2-) advanced breast cancer in the United States. J Med Econ (2012) 2.05
The prevalence and correlates of nonaffective psychosis in the National Comorbidity Survey Replication (NCS-R). Biol Psychiatry (2005) 2.03
Annual costs associated with diagnosis of uterine leiomyomata. Obstet Gynecol (2006) 1.96
Real-world practice patterns, health-care utilization, and costs in patients with low back pain: the long road to guideline-concordant care. Spine J (2011) 1.84
Effects of adalimumab therapy on incidence of hospitalization and surgery in Crohn's disease: results from the CHARM study. Gastroenterology (2008) 1.78
Patient-reported health status in coronary heart disease in the United States: age, sex, racial, and ethnic differences. Circulation (2008) 1.39
Impact of cardiometabolic risk factor clusters on health-related quality of life in the U.S. Obesity (Silver Spring) (2007) 1.28
Impact of stroke on health-related quality of life in the noninstitutionalized population in the United States. Stroke (2006) 1.24
Effects of adalimumab maintenance therapy on health-related quality of life of patients with Crohn's disease: patient-reported outcomes of the CHARM trial. Am J Gastroenterol (2008) 1.21
Therapy persistence and adherence in patients with chronic obstructive pulmonary disease: multiple versus single long-acting maintenance inhalers. J Med Econ (2011) 1.19
Comparative effectiveness without head-to-head trials: a method for matching-adjusted indirect comparisons applied to psoriasis treatment with adalimumab or etanercept. Pharmacoeconomics (2010) 1.10
Increased risks of developing anxiety and depression in young patients with Crohn's disease. Am J Gastroenterol (2011) 1.10
Incremental third-party costs associated with COPD exacerbations: a retrospective claims analysis. J Med Econ (2011) 1.10
Cost-effectiveness of hub-and-spoke telestroke networks for the management of acute ischemic stroke from the hospitals' perspectives. Circ Cardiovasc Qual Outcomes (2012) 1.09
Productivity costs associated with cardiometabolic risk factor clusters in the United States. Value Health (2007) 1.08
Hypoglycemia, treatment discontinuation, and costs in patients with type 2 diabetes mellitus on oral antidiabetic drugs. Postgrad Med (2012) 1.08
Re.: Cost-effectiveness of denosumab vs zoledronic acid for prevention of skeletal-related events in patients with solid tumors and bone metastases in the United States. J Med Econ (2012) 1.07
Adherence and Persistence Among Chronic Myeloid Leukemia Patients During Second-Line Tyrosine Kinase Inhibitor Treatment. J Manag Care Spec Pharm (2015) 1.06
Matching-adjusted indirect comparisons: a new tool for timely comparative effectiveness research. Value Health (2012) 1.03
Inhaled corticosteroids or long-acting beta-agonists alone or in fixed-dose combinations in asthma treatment: a systematic review of fluticasone/budesonide and formoterol/salmeterol. Clin Ther (2009) 1.02
Cost per responder associated with biologic therapies for Crohn's disease, psoriasis, and rheumatoid arthritis. Adv Ther (2012) 1.01
Short-term economic impact of body weight change among patients with type 2 diabetes treated with antidiabetic agents: analysis using claims, laboratory, and medical record data. Curr Med Res Opin (2007) 1.01
Reduced mortality in cystic fibrosis patients treated with tobramycin inhalation solution. Pediatr Pulmonol (2011) 0.99
Treatment patterns and symptom control in patients with GERD: US community-based survey. Curr Med Res Opin (2009) 0.98
Treatment patterns and duration in post-menopausal women with HR+/HER2- metastatic breast cancer in the US: a retrospective chart review in community oncology practices (2004-2010). Curr Med Res Opin (2014) 0.95
Economic burden of psoriasis compared to the general population and stratified by disease severity. Curr Med Res Opin (2009) 0.94
The effect of adalimumab on reducing depression symptoms in patients with moderate to severe psoriasis: a randomized clinical trial. J Am Acad Dermatol (2010) 0.92
Comparative efficacy of nilotinib and dasatinib in newly diagnosed chronic myeloid leukemia: a matching-adjusted indirect comparison of randomized trials. Curr Med Res Opin (2011) 0.92
Clinical and economic outcomes of multiple versus single long-acting inhalers in COPD. Respir Med (2011) 0.90
Comparison of two adalimumab treatment schedule strategies for moderate-to-severe Crohn's disease: results from the CHARM trial. Am J Gastroenterol (2009) 0.90
Efficacy and safety of adalimumab among patients with moderate to severe psoriasis with co-morbidities: Subanalysis of results from a randomized, double-blind, placebo-controlled, phase III trial. Am J Clin Dermatol (2011) 0.90
Association between molecular monitoring and long-term outcomes in chronic myelogenous leukemia patients treated with first line imatinib. Curr Med Res Opin (2013) 0.89
Healthcare and workloss costs associated with patients with persistent asthma in a privately insured population. J Occup Environ Med (2006) 0.88
Comparative effectiveness research using matching-adjusted indirect comparison: an application to treatment with guanfacine extended release or atomoxetine in children with attention-deficit/hyperactivity disorder and comorbid oppositional defiant disorder. Pharmacoepidemiol Drug Saf (2012) 0.86
Everolimus and sunitinib for advanced pancreatic neuroendocrine tumors: a matching-adjusted indirect comparison. Exp Hematol Oncol (2013) 0.86
Association between regular molecular monitoring and tyrosine kinase inhibitor therapy adherence in chronic myelogenous leukemia in the chronic phase. Curr Med Res Opin (2014) 0.86
Evaluation of compliance and health care utilization in patients treated with single pill vs. free combination antihypertensives. Curr Med Res Opin (2010) 0.85
Cost-effectiveness of adalimumab for the maintenance of remission in patients with Crohn's disease. Eur J Gastroenterol Hepatol (2009) 0.85
Risks of developing psychiatric disorders in pediatric patients with psoriasis. J Am Acad Dermatol (2012) 0.85
Comparing treatment adherence of lisdexamfetamine and other medications for the treatment of attention deficit/hyperactivity disorder: a retrospective analysis. J Med Econ (2013) 0.84
Medical resource use and costs associated with chylomicronemia. J Med Econ (2013) 0.83
Outcomes in atrial fibrillation patients on combined warfarin & antiarrhythmic therapy. Int J Cardiol (2012) 0.83
Matching-adjusted indirect comparison of adalimumab vs etanercept and infliximab for the treatment of psoriatic arthritis. J Med Econ (2013) 0.83
Development and validation of a claims-based prediction model for COPD severity. Respir Med (2013) 0.83
Economic benefits of adequate molecular monitoring in patients with chronic myelogenous leukemia. J Med Econ (2013) 0.82
Use of inhaled corticosteroids and healthcare costs in mild persistent asthma. J Asthma (2007) 0.82
A retrospective analysis of therapy adherence in imatinib resistant or intolerant patients with chronic myeloid leukemia receiving nilotinib or dasatinib in a real-world setting. Curr Med Res Opin (2012) 0.82
Distribution and drivers of costs in type 2 diabetes mellitus treated with oral hypoglycemic agents: a retrospective claims data analysis. J Med Econ (2014) 0.82
Clinical and economic benefits associated with the achievement of both HbA1c and LDL cholesterol goals in veterans with type 2 diabetes. Diabetes Care (2013) 0.82
Monitoring and switching patterns of patients with chronic myeloid leukemia treated with imatinib in community settings: a chart review analysis. Curr Med Res Opin (2012) 0.82
The epidemiology and targeted therapies for relapsed and refractory CD30+ lymphomas. Curr Med Res Opin (2015) 0.81
High prevalence of potential drug-drug interactions for psoriasis patients prescribed methotrexate or cyclosporine for psoriasis: associated clinical and economic outcomes in real-world practice. Dermatology (2010) 0.81
The role of health economics and outcomes research in health care reform in China. Pharmacoeconomics (2014) 0.81
Cost-effectiveness analysis of roflumilast/tiotropium therapy versus tiotropium monotherapy for treating severe-to-very severe COPD. J Med Econ (2011) 0.81
Achieving glycemic goal with initial versus sequential combination therapy using metformin and pioglitazone in type 2 diabetes mellitus. Curr Med Res Opin (2010) 0.81
Prevalence and risk of developing comorbid conditions in patients with chronic constipation. Curr Med Res Opin (2014) 0.81
Cost effectiveness of guanfacine extended release as an adjunctive therapy to a stimulant compared with stimulant monotherapy for the treatment of attention-deficit hyperactivity disorder in children and adolescents. Pharmacoeconomics (2012) 0.80
Major molecular response during the first year of dasatinib, imatinib or nilotinib treatment for newly diagnosed chronic myeloid leukemia: a network meta-analysis. Cancer Treat Rev (2013) 0.80
The economic burden of pleural effusions in patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors. J Med Econ (2012) 0.80
Everolimus use and associated factors among post-menopausal women with hormonal receptor positive/human epidermal growth factor receptor 2 negative metastatic breast cancer. Curr Med Res Opin (2015) 0.79
Comparative treatment patterns, resource utilization, and costs in stimulant-treated children with ADHD who require subsequent pharmacotherapy with atypical antipsychotics versus non-antipsychotics. J Manag Care Pharm (2012) 0.79
Chart review of patients on valsartan-based single-pill combinations vs. ARB-based free combinations for BP goal achievement. Curr Med Res Opin (2010) 0.79
One-year and long-term molecular response to nilotinib and dasatinib for newly diagnosed chronic myeloid leukemia: a matching-adjusted indirect comparison. Curr Med Res Opin (2014) 0.79
Identifying patient subgroups who benefit most from a treatment: using administrative claims data to uncover treatment heterogeneity. J Med Econ (2012) 0.79
A longitudinal analysis of costs associated with change in disease activity in systemic lupus erythematosus. J Med Econ (2013) 0.78
Impact of initiation timing of SSRI or SNRI on depressed adolescent healthcare utilization and costs. J Med Econ (2011) 0.78
A pulmonary exacerbation risk score among cystic fibrosis patients not receiving recommended care. Pediatr Pulmonol (2012) 0.78
Cost-effectiveness of denosumab compared with zoledronic acid in patients with breast cancer and bone metastases. Clin Breast Cancer (2012) 0.78
Comparative effectiveness of everolimus-based therapy versus endocrine monotherapy among postmenopausal women with HR+/HER2- metastatic breast cancer: a retrospective chart review in community oncology practices in the US. Curr Med Res Opin (2015) 0.78
Comparison of the long-term risk of recurrence and other clinical outcomes in GIST patients receiving imatinib as adjuvant therapy--a retrospective chart extract-based approach. J Gastrointest Cancer (2013) 0.78
Comparing healthcare costs of Medicaid patients with postherpetic neuralgia (PHN) treated with lidocaine patch 5% versus gabapentin or pregabalin. J Med Econ (2010) 0.78
Retrospective economic and outcomes analyses using non-US databases: a review. Pharmacoeconomics (2007) 0.78
Treatment patterns, prescribing decision drivers, and predictors of complete response following disease recurrence in gastrointestinal stromal tumor patients-a chart extract-based approach. J Gastrointest Cancer (2014) 0.78
Cost-effectiveness of metformin plus vildagliptin compared with metformin plus sulphonylurea for the treatment of patients with type 2 diabetes mellitus: a Portuguese healthcare system perspective. J Med Econ (2014) 0.77
Treatment patterns, health care resource utilization, and costs in U.S. patients diagnosed with chronic hepatitis C infection who received telaprevir or boceprevir. J Manag Care Spec Pharm (2015) 0.77
Impact of atypical antipsychotic use among adolescents with attention-deficit/hyperactivity disorder. Am J Manag Care (2014) 0.77
Period prevalence of concomitant psychotropic medication usage among children and adolescents with attention-deficit/hyperactivity disorder during 2009. J Child Adolesc Psychopharmacol (2014) 0.77
Copayment level, treatment persistence, and healthcare utilization in hypertension patients treated with single-pill combination therapy. J Med Econ (2011) 0.77
Economic burden of dermatologic adverse drug reactions in the treatment of colorectal, non-small cell lung, and head and neck cancers with epidermal growth factor receptor inhibitors. J Med Econ (2012) 0.77
Study of imatinib treatment patterns and outcomes among US veteran patients with Philadelphia chromosome-positive chronic myeloid leukemia. J Oncol Pract (2013) 0.77
Persistence with nebivolol in the treatment of hypertension: a retrospective claims analysis. Curr Med Res Opin (2012) 0.77
Demonstrating the burden of hypoglycemia on patients' quality of life in diabetes clinical trials: measurement considerations for hypoglycemia. Value Health (2012) 0.77
Healthcare costs associated with bevacizumab and cetuximab in second-line treatment of metastatic colorectal cancer. J Med Econ (2011) 0.77
Assessing the relationship between compliance with antidepressant therapy and employer costs among employees in the United States. J Occup Environ Med (2010) 0.77
Cost utility of hub-and-spoke telestroke networks from societal perspective. Am J Manag Care (2013) 0.77
Descriptive analysis of Medicaid patients with postherpetic neuralgia treated with lidocaine patch 5%. J Med Econ (2010) 0.76
Pre-diagnosis excess acute care costs in Alzheimer's patients among a US Medicaid population. Appl Health Econ Health Policy (2013) 0.76
The economic burden of gastrointestinal stromal tumor (GIST) recurrence in patients who have received adjuvant imatinib therapy. J Med Econ (2014) 0.76